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Antigen-Specific Suppression of a Primed Immune
Response by Dendritic Cells Mediated
by Regulatory T Cells Secreting Interleukin-10
defined. However, B cells deprived of signaling through
CD40 have been shown to induce T cell tolerance (Buhl-
mann et al., 1995; Hollander et al., 1996). A role for DCs
in the induction of peripheral tolerance through Treg has
been supported by several recent studies. The ability of
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Brisbane, Queensland 4102 myeloid DC to induce immunity or tolerance appears to
be linked to its maturation state (Dhodapkar et al., 2001;Australia
Jonuleit et al., 2000; Lutz et al., 2000; Mehling et al.,
2000). Immature DCs generated from murine BM in-
duced T cell unresponsiveness in vitro and prolongedSummary
cardiac allograft survival in a preventive model (Lutz et
al., 2000). Immature myeloid DCs induced CD4 Treg inAntigen-specific suppression of a previously primed
immune response is a major challenge for immuno- vitro and CD8 Treg in vivo which each produced high
levels of IL-10 and low levels of IFN- but no IL-4 (Dho-therapy of autoimmune disease. RelB activation is re-
quired for myeloid DC differentiation. Here, we show dapkar et al., 2001; Jonuleit et al., 2000). Various drugs
and cytokines, and inhibitors of NFB have been shownthat antigen-exposed DCs in which RelB function is
inhibited lack cell surface CD40, prevent priming of to inhibit myeloid DC maturation (de Jong et al., 1999;
Griffin et al., 2001; Hackstein et al., 2001; Lee et al., 1999;immunity, and suppress previously primed immune
responses. DCs generated from CD40-deficient mice Mehling et al., 2000; Steinbrink et al., 1997; Yoshimura et
al., 2001). DCs generated in the presence of these agentssimilarly confer suppression. Regulatory CD4 T cells
induced by the DCs transfer antigen-specific “infec- altered T cell function in vitro and in vivo, including
promotion of allograft survival (Giannoukakis et al., 2000;tious” tolerance to primed recipients in an interleukin-
10-dependent fashion. Thus CD40, regulated by RelB Griffin et al., 2001). Despite this, suppression of pre-
viously primed CD4 T cell responses by DCs in vivoactivity, determines the consequences of antigen pre-
sentation by myeloid DCs. These observations have has not been demonstrated. This is important for therapy
of preexisting autoimmune disease as CD4 effectorsignificance for autoimmune immunotherapy and sug-
gest a mechanism by which peripheral tolerance might T cells mediate the perpetuation of tissue damage in
autoimmune disease through their interaction with mono-be constitutively maintained by RelB CD40 DCs.
cytes, B cells, and local DCs (Feldmann, 2001).
NFB activity leads to transcription of a number ofIntroduction
genes involved in the immune response. RelB activity
is required for myeloid DC differentiation (Burkly et al.,Antigen-specific suppression of a previously primed im-
mune response is a major challenge for immunotherapy 1995; Weih et al., 1995; Wu et al., 1998). In particular,
we have shown that RelB regulates B cell APC functionof autoimmune disease. Blockade of products of the
innate immune system, including TNF- and IL-1, pro- through regulation of CD40 and MHC molecule expres-
sion (O’Sullivan et al., 2000). Therefore, we hypothesizedduces dramatic anti-destructive clinical effects in the
autoimmune disease rheumatoid arthritis (RA) (reviewed that deficiency of RelB activity in DCs would be sufficient
for suppression of immune responses by myeloid DCs.by Feldmann, 2001). However, this approach is non anti-
gen-specific and is reversible in the absence of treat-
ment. Novel approaches include reinstitution of control Results
on self-antigen presentation, derived from regulatory T
cells (Treg). Suppression of immune effector cells by Inhibition of Myeloid DC Differentiation and Antigen-
a variety of described Treg is a key mechanism for pe- Specific Suppression of Primed Immune Responses
ripheral tolerance (Maloy and Powrie, 2001). However, by Inhibition of RelB Function
for control of preexisting autoimmune or other immune Translocation of the NFB family members RelB and
responses, it will be important to understand the major p50 from cytoplasm to nucleus is required for myeloid
determinants of regulation of antigen presentation by APC. DC maturation. To assess the relationship between
The complex interactions resulting in the generation RelB, differentiation, and tolerance induction by myeloid
of T cell-mediated immune responses are dependent DCs, BMDCs were generated from homozygous H-2b
on antigen presentation, cognate interactions between RelB/ or wild-type H-2b mice. RelB/ BMDCs ex-
T cells and antigen-presenting cells (APCs) including pressed no CD40 and expressed lower levels of MHC
dendritic cells (DCs), and the concomitant production class II and CD86 than RelB/ BMDCs (Figure 1A). The
of soluble and membrane costimulatory molecules by ability of s.c. adoptively transferred methylated BSA
APCs and T cells. DCs are implicated in the establish- (mBSA)-pulsed RelB/ BMDCs to prime an antigen-
ment and maintenance of self tolerance—both centrally specific T cell proliferative response in naive wild-type
and in the periphery. The molecular mechanisms con- H-2b mice was reduced, compared with mBSA-pulsed
trolling DC function in tolerance and immunity are poorly RelB/ BMDCs (Figure 1B). To test tolerance induction,
wild-type H-2b mice were injected s.c. with 5 105 KLH-
pulsed DCs 7 days before or 7 days after priming with*Correspondence: rthomas@cicr.uq.edu.au
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Figure 1. Suppression of Primed Immune Responses by RelB-Deficient BMDCs
BMDCs were generated from wild-type or RelB/ mice, and cell surface markers were analyzed by flow cytometry (A). Wild-type mice were
injected with BMDCs or mBSA in CFA as shown, and DLN mBSA-specific T cell proliferation was examined 7 days later (B). Wild-type mice
were injected with BMDCs or saline as shown, 7 days before or after immunization with KLH in CFA (C). DLN KLH-specific T cell proliferation
and ear KLH-specific DTH responses are shown. Mean  SEM cpm from groups of five mice tested individually are shown. Results are
representative of two separate experiments. ** p 	 0.01, compared with wild-type DCs  mBSA.
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KLH in CFA. KLH-specific immunity was tested 5 days
after DC or KLH administration. Administration of DCs
generated from RelB/ BM not only prevented priming
of specific immunity by subsequent administration of
KLH/CFA, but also suppressed a previously primed
immune response when administered 7 days after im-
munization with KLH/CFA (Figure 1C). In contrast, no
suppression of KLH-specific immunity was observed
following administration of KLH-pulsed RelB/ DCs,
whether these DCs were administered prior to or follow-
ing immunization (Figure 1C).
To independently assess the relationship between
RelB nuclear translocation and tolerance induction,
BMDCs were generated in the presence or absence of
the compound BAY 11-7082 (BAY). BAY has been shown
to block TNF--stimulated NFB translocation through
inhibition of IB phosphorylation (Pierce et al., 1997).
Murine BM precursors were incubated for 6 days with
GM-CSF and IL-4 to produce BMDCs, in the presence
or absence of BAY. All NFB subunits were demonstra-
ble in BMDCs generated in the absence of BAY and
were present in both nuclear and cytoplasmic extracts
(Figure 2A). In contrast, BMDCs generated in the pres-
ence of BAY demonstrated NFB subunit immunoreac-
tivity in the cytoplasm but not the nucleus (Figure 2A).
BMDCs generated in the presence of BAY were similar
in phenotype to RelB-deficient DCs, in that they lacked
cell surface CD40 expression, and expressed reduced
levels of MHC class I and class II (Figure 2B). However,
CD86 was expressed at higher levels in BAY-treated
DCs than RelB-deficient DCs. BMDC populations gener-
ated in the presence or absence of BAY had a dendritic
morphology and expressed CD11b and low levels of F4/
80 but no CD8, CD3, CD19, Gr-1, or CD45R (data not
shown). The ability of adoptively transferred BAY-
treated DCs to prime an mBSA-specific T cell prolifera-
tive response in naive syngeneic mice when pulsed with
the antigen mBSA was reduced, compared with mBSA-
pulsed untreated BMDCs or immunization with mBSA
and CFA (Figure 2C).
BAY-treated DCs were administered to mice 7 days
before or 7 days after immunization with mBSA in CFA.
mBSA-specific immunity was tested 5 days after DC or
mBSA administration. mBSA-pulsed BAY-treated DCs
prevented priming and conferred suppression of mBSA-
specific immunity when compared to mBSA-pulsed DCs
Figure 2. DC Differentiation in the Presence of an Inhibitor of NFB
that had not been exposed to BAY (Figures 3A and 3B). Translocation Inhibits CD40 Expression and APC Function
mBSA-specific T cell proliferation, Ab production, and BMDCs were generated in the presence or absence of BAY 11-
DTH responses were each suppressed after administra- 7082. Nuclear and cytoplasmic extracts were immunoblotted for
tion of antigen-exposed BAY-treated DCs. The data indi- NFB subunits as shown (A). Cell surface marker expression was
analyzed by flow cytometry (B). Naive C57BL/6 mice were injectedcate that DCs in which RelB function is inhibited lack
s.c. as shown. DLN T cell proliferation in vitro in response to exoge-CD40, prevent subsequent priming of immunity, and
nous mBSA is displayed as mean  SEM cpm of triplicates of fivesuppress a previously primed immune response in vivo.
mice assayed individually (C). Results are representative of three
The antigen specificity of suppression and the effect separate experiments. ** p 	 0.005, *** p 	 0.001 compared with
of dose and route of immunization were tested by com- DCs  mBSA.
paring the DTH responses to KLH and to mBSA after
administration of varying doses of mBSA-pulsed BAY-
treated DCs given i.v. or s.c. Mice injected with mBSA-
pulsed BAY-treated DCs were tolerant to subsequent 105 mBSA-pulsed BAY-treated DCs and subsequently
priming with mBSA in CFA, in a route-independent fash- primed with KLH in CFA (Figure 3D). The data indicate
ion, and greater numbers of DCs were more effective that the tolerance induced by BAY-treated DCs is DC
at inducing tolerance (Figure 3C). There was no reduc- dose dependent and specific for the antigen to which
the DCs have been exposed. The lack of suppressiontion in KLH DTH responses in mice preinjected with 5 
Immunity
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Figure 3. Suppression of Primed Immune Responses by Inhibition of RelB Function of DCs
Mice were injected s.c. with BMDCs or saline as shown, 7 days before (A) or after (B) priming with mBSA in CFA. 5 days later, mice were
individually tested for DLN antigen-specific T cell proliferative, serum antibody, and ear DTH responses.
7 days after s.c. or i.v immunization with varying doses of mBSA-pulsed BAY-treated BMDCs or no DCs, mice were injected with mBSA in CFA
(C) or KLH in CFA (D). DTH responses to mBSA or KLH were measured 5 days later. (E) 5  105 KLH-pulsed H-2b wild-type or MHC class
II/ BMDCs generated in the presence or absence of BAY were administered to wild-type mice 7 days after immunization with KLH in CFA.
KLH-specific immunity was tested 5 days after DC administration. Results are displayed as the mean  SEM for each group (n 
 5), tested
separately, and are representative of three separate experiments. NS, not significant; * p 	 0.01, ** p 	 0.001.
of the KLH DTH response also excludes carry over of While injected DCs are likely to present antigen di-
rectly to T cells in draining LN, it was possible thatnonspecific suppressive effects by residual soluble in-
hibitor to draining LN lymphocytes. antigen-exposed injected DCs could be crosspresented
IL-10, Tolerance, and Dendritic Cells
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by host DCs in recipient mice. To address this, 5  105 either CD40/ or CD40/ BM in the presence of BAY
(Figures 5B and 5C).KLH-pulsed H-2b wild-type or MHC class II/ BMDCs
generated in the presence or absence of BAY were ad-
ministered to wild-type mice 7 days after immunization In the Absence of RelB or CD40, DCs Induce CD4
with KLH in CFA. KLH-specific immunity was tested 5 Regulatory T Cells that Confer Infectious Tolerance
days after DC administration. KLH-pulsed BAY-treated The systemic nature of the conferred suppression sug-
wild-type DCs conferred suppression of KLH-specific gested that in the absence of CD40 or RelB activity, DCs
immunity when compared to KLH-pulsed BAY-treated might induce Treg in the recipient animal. This possibility
MHC class II/ DCs or KLH-pulsed wild-type DCs that was examined in two ways. First, we tested whether
had not been exposed to BAY. Neither KLH-specific T induced Treg could transfer tolerance to naive or primed
cell proliferation (data not shown) nor DTH responses were recipient animals (infectious tolerance) (Cobbold and
suppressed after administration of antigen-exposed BAY- Waldmann, 1998). 5  105 flow cytometrically sorted
treated MHC class II/ DCs (Figure 3E). The data indicate CD4 or CD4 T cells derived from spleens of mice
that MHC class II expression by the injected DCs is injected s.c. with KLH-pulsed BAY-treated BMDCs were
necessary for subsequent suppression, thereby provid- transferred to syngeneic recipients primed 9 days pre-
ing evidence that injected BAY-treated antigen-exposed viously with either KLH or ovalbumin and CFA. Antigen-
DCs are not crosspresented by recipient DCs. specific T cell responses were determined 7 days after
T cell transfer. Adoptive transfer of CD4 T cells derived
from mice previously treated with KLH-pulsed BAY-Suppression of Primed Immune Responses
treated BMDCs strongly suppressed the subsequentby DCs Correlates with Their RelB Nuclear
KLH-specific T cell proliferative responses in recipientBinding Activity and CD40 Expression
mice, when compared with CD4 or CD4 T cells fromPreviously, immature BM or monocyte-derived DCs
mice treated with KLH-pulsed untreated BMDCs (Fig-have been shown to regulate immune responses. Since
ures 6A and 6B). Suppression by CD4 T cells derivedDCs in which RelB nuclear translocation is inhibited
from mice previously treated with KLH-pulsed BAY-suppressed a primed immune response, the capacity
treated BMDCs was modest or absent over a numberof DCs prepared ex vivo to suppress immunity was cor-
of experiments. The OVA-specific T cell proliferative re-related with RelB activity in nuclear extracts. BMDCs
sponse in the recipient mice was unaffected by T cellwere generated in medium containing serum and either
transfers. Since T cells were identically sorted for thisGM-CSF and IL-4 (control DCs), GM-CSF alone (“imma-
group, it is unlikely that the labeling mAb themselvesture DCs”) (Lutz et al., 2000), or BAY, GM-CSF, and IL-4,
induced suppressive capacity by the T cells.then pulsed with KLH and injected s.c. into mice primed
Second, cytokine production by CD4 T cells in LN7 days previously with KLH and CFA. Immature DCs
draining the site of antigen-exposed DC immunizationexpressed lower levels of CD86, CD40, and class II than
was compared ex vivo. When compared with the CD4control DCs. By contrast, BAY-treated DCs expressed
T cells in LN draining the site of antigen-pulsed wild-higher levels of CD86 and reduced CD40 compared with
type DCs, a greater proportion of CD4 T cells in LNimmature DCs (Figure 4A). Suppression by DCs of KLH-
draining the site of injection of either antigen-pulsedspecific draining LN T cell responses correlated with
RelB/ DCs, BAY-treated DCs, or CD40/ DCs pro-the binding capacity of RelB and p50 in nuclear extracts
duced IL-10 in response to in vitro restimulation withto an NFB consensus oligonucleotide, and with CD40
either PMA or with KLH (Table 1). In contrast, a greaterexpression (Figure 4). Immunocytochemical staining of
proportion of T cells primed by KLH-pulsed wild-typeDC populations showed that the proportion of DCs that
DCs produced IFN- in response to PMA or to KLH inhad translocated RelB to the nucleus within each popu-
vitro. IL-4 production was minimal in all draining LNslation correlated with total RelB and p50 binding capac-
(data not shown). Taken together, the data indicate thatity (data not shown).
DCs lacking CD40 expression or RelB function induce
the differentiation of CD4 Treg that are capable of pro-
ducing IL-10 in an antigen-specific manner.CD40 Deficiency Is Sufficient to Confer
Suppression of Immunity by DCs To determine whether the IL-10 produced by the CD4
Treg was responsible for the observed suppression ofSince RelB-deficient and BAY-treated BMDCs lacked
cell surface CD40, and suppression of immunity by DCs immunity, 5  105 DCs generated from BM of H-2b wild-
type mice in the presence or absence of BAY werecorrelated with CD40 expression, we determined
whether lack of CD40 expression by antigen-exposed pulsed with KLH and administered s.c. to naive IL-10/
or IL-10/ H-2b mice. CD4 T cells were magneticallyBMDCs was sufficient for suppression of previously
primed immunity. DCs generated from CD40/ BM in sorted by negative selection from recipient spleens 7
days later, and 2.5  105 cells were transferred to wild-the presence or absence of BAY were similar in pheno-
type to RelB-deficient DCs, except for higher cell surface type mice primed 7 days previously with KLH in CFA.
Adoptive transfer of CD4 T cells derived from IL-10/CD86 expression (Figure 5A). DCs generated from BM
of H-2d CD40/ or CD40/ mice in the presence or mice previously treated with KLH-pulsed BAY-treated
BMDCs strongly suppressed the subsequent KLH-spe-absence of BAY were pulsed with KLH and administered
s.c. to wild-type H-2d mice 7 days after priming with cific DTH and T cell proliferative responses (data not
shown) in recipient mice, when compared with CD4KLH in CFA. Administration of DCs generated from
CD40/ BM conferred equivalent suppression of a pre- derived from IL-10/mice treated with KLH-pulsed BAY
treated BMDCs (Figure 6C). Furthermore, adoptiveviously primed immune response to DCs generated from
Immunity
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Figure 4. Suppression of Primed Responses by DCs Correlates with RelB Nuclear Binding Activity
BMDCs were generated in either GM-CSF and IL-4 (control), GM-CSF alone (immature), or GM-CSF and IL-4 in the presence of BAY, and cell
surface markers were analyzed (A). Mice were primed with KLH in CFA and 7 days later injected with DCs or saline as shown. KLH-specific
T cell proliferative responses were measured after 5 days (B). Nuclear extracts from DCs were bound to ELISA plates coated with NFB
consensus oligonucleotides and detected with either anti-RelB or anti-p50 (C). * p 	 0.05, ** p 	 0.01, and *** p 	 0.0001.
IL-10, Tolerance, and Dendritic Cells
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Figure 5. CD40 Deficiency Is Sufficient to Confer Suppression of Immunity by DCs
BMDCs were generated from CD40/ or wild-type H-2d mice in the presence or absence or BAY, and cell surface markers were analyzed
by flow cytometry (A). Mice were injected with BMDCs or saline as shown, 7 days after immunization with KLH in CFA. DLN KLH-specific T
cell proliferation (B) and ear KLH-specific DTH responses (C) are shown. Mean  SEM cpm from groups of five mice tested individually are
shown. * p 	 0.05, ** p 	 0.01, and *** p 	 0.0001.
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Figure 6. Antigen-Specific Tolerance Is Infectious and IL-10 Dependent
Mice were injected with 5  105 BMDCs as shown. Spleens were collected after 7 days, and 5  105 CD4CD3 or CD4CD3 cells sorted
from nylon wool purified preparations were injected i.v. into nonirradiated KLH or OVA-primed syngeneic mice. Mean  SEM cpm, KLH- or
OVA-specific T cell proliferative responses in DLN (A) or DTH responses (B) measured 7 days later from groups of three mice tested individually
are shown. (C and D) 5  105 DCs generated from BM of H-2b wild-type mice in the presence or absence of BAY were pulsed with KLH and
administered s.c. to naive IL-10/ (black bars) or IL-10/ (white bars) H-2b mice. CD4 T cells were magnetically sorted by negative selection
from recipient spleens 7 days later, and 2.5  105 cells were transferred to wild-type mice primed 7 days previously with KLH in CFA. In (D),
anti-IL10R or isotype control mAb were administered i.p. to primed recipients 4 hr before T cell transfer. *** p 	 0.0001, ** p 	 0.001.
transfer of CD4 T cells derived from IL-10/ donors ent mice administered isotype control mAb, but adminis-
tration of IL-10R mAb to recipients blocked suppressionpreviously treated with KLH-pulsed BAY-treated BMDCs
strongly suppressed the subsequent KLH-specific DTH by the T cells (Figure 6D). The data indicate that antigen-
exposed DCs in which RelB function is inhibited induceand T cell proliferative responses (not shown) in recipi-
IL-10, Tolerance, and Dendritic Cells
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Table 1. Cytokine Production by T Cells in Draining LN
% CD4IL-10 Cells % CD4IFN Cells
Ex Vivo Treatment PMA In Vitro (mean %  SD)
Experiment 1, H-2b mice
DCs 0.62  0.22 0.8  0.11
DCs  KLH 0.52  0.15 2.5  0.62
DCs  BAY  KLH 11.23  0.18 1.62  0.29
RelB/ DCs  KLH 3.5  0.05 0.7  0.11
Experiment 2, H-2d mice
DCs 0.9  0.8 1.3  0.2
DCs  KLH 1.1  0.5 3.9  0.8
CD40/ DCs  KLH 4.7  0.2 1.8  0.5
CD40/ DCs  BAY  KLH 5.4  0.01 2.7  0.2
KLH In VitroExperiment 3, H-2b mice
DCs 0.34  0.32 0.98  0.21
DCs  KLH 1.97  0.5 3.3  0.52
DCs  BAY  KLH 3.76  0.3 0.4  0.01
Medium Control In Vitro
DCs 0.1  0.03 0.2  0.08
DCs  KLH 0.2  0.06 0.32  0.07
DCs  BAY  KLH 0.12  0.01 0.16  0.05
OVA In Vitro
DCs 0.16  0.01 0.19  0.06
DCs  KLH 0.11  0.03 0.2  0.02
DCs  BAY  KLH 0.09  0.02 0.1  0.05
H-2b mice were injected with KLH-pulsed DCs generated from RelB/ or RelB/ BM in the presence or absence of BAY (experiment 1), or H-2d
mice were injected with KLH-pulsed DCs generated from CD40/ or CD40/ BM in the presence or absence of BAY (experiment 2). H-2b mice
were injected with KLH-pulsed DCs generated from BM in the presence or absence of BAY (experiment 3). Control mice were injected with
DCs alone. After 5 days, DLN cells were incubated in vitro with either PMA/Ionomycin (experiments 1 and 2), KLH, ovalbumin, or serum-free
medium (experiment 3) for 18 hr in the presence of brefeldin A, then stained with CD4-PE and either IL-10-APC or IFN--APC. Mean  SD
% cytokine-expressing CD4 T cells from groups of five mice tested individually are shown.
a population of antigen-specific CD4 regulatory T cells 2002). BMDCs generated from RelA/p50 doubly defi-
cient mice were more prone to death, and BMDCs gener-that regulate immune responses in an IL-10-dependent
manner. ated from c-Rel/p50-deficient mice showed intact CD40
expression and APC function in MLR (when corrected
for viability) but reduced IL-12 production. LPS-inducedDiscussion
upregulation of MHC molecules, ICAM-1, CD80, and
CD86 was unaffected in c-Rel/p50-deficient mice. TakenWe show here that antigen-exposed myeloid DCs, in
together with the current and with previous studies, thesewhich RelB function is inhibited, lack cell surface CD40
data indicate that RelA, RelB, and c-Rel—partneringexpression, prevent priming of immunity, and suppress
with p50—each play unique and complementary rolesa previously primed immune response. DCs in which
in the process of myeloid DC differentiation (Grumont etRelB nuclear translocation is inhibited through preven-
al., 2001; Neumann et al., 2000; O’Sullivan and Thomas,tion of IkB phosphorylation, DCs generated from RelB-
2002; Rescigno et al., 1998). In particular, RelB/p50 spe-deficient mice, and DCs generated from CD40-deficient
cifically controls functional myeloid DC differentiationmice similarly conferred suppression. Thus, while in
and CD40 expression. A similar role for RelB and CD40vitro-derived immature BMDCs share some characteris-
in determining the consequences of presentation of anti-tics of the BAY-treated BMDCs, including modest induc-
gen by B cells has also emerged (Buhlmann et al., 1995;tion of tolerance, CD40—as opposed to DC immaturity—
Hollander et al., 1996; O’Sullivan et al., 2000; Pai et al.,determines the consequences of presentation of antigen
2002).by myeloid DCs. In this regard, DCs in which NFB
Induction of suppression was specific for the antigenactivity was suppressed during development from BM
to which DCs had been exposed. Moreover, this sup-precursors, or CD40-deficient DCs expressed levels of
pression results from induction of antigen-specific Treg,CD86 equivalent to those of mature DCs and higher than
as DC administration increased the proportion of CD4those expressed by immature DCs. Furthermore, CD40
T cells producing IL-10 in draining LN, and CD4 spleniclevels were lower than those expressed by immature
T cells from tolerant animals transferred antigen-specificBM DCs.
tolerance to primed recipients in an IL-10-dependentThe current data indicate that deficiency in RelB
manner. Therefore, the DCs induced an active infectiousactivity leads to the generation of DCs with a unique
process of antigen-specific regulation (Cobbold andCD40-deficient phenotype. Recently, the phenotype and
Waldmann, 1998). While the exact phenotype of theviability of BMDCs generated from RelA-, c-Rel-, and
p50-deficient mice were demonstrated (Ouaaz et al., CD4 Treg induced in the current studies is not yet
Immunity
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elucidated, they most closely resemble Tr1 cells. Anti- hand, the involvement of CD40-CD154 in priming of T
cell responses to infectious organisms varies depend-gen-specific Tr1 cells induced in vitro produce IL-10
and suppress inflammation in colitis and allergic models ing on the organism. Thus, Th1-mediated resistance to
several organisms, including Toxoplasma gondii, andin an IL-10-dependent manner (Groux et al., 1997). In
keeping with the current studies demonstrating that Th2-mediated resistance to Schistosoma mansoni are
impaired in the absence of CD40-CD154 interactionssuppression of primed immune responses by DCs corre-
lates with their RelB nuclear binding activity and CD40 (MacDonald et al., 2002a; Subauste et al., 1999). In con-
trast, CD40-CD154 appears not to be required for theexpression, human immature monocyte-derived my-
eloid DCs also induced CD8 T regulatory cells in vivo, Th1 response to either Proprionibacterium acnes or His-
toplasma capsulatum (MacDonald et al., 2002b; Zhouwhich produced high levels of IL-10 and low levels of
IFN- but no IL-4 (Dhodapkar et al., 2001). and Seder, 1998). These studies strongly implicate a
CD40- and NFB-independent mechanism of DC activa-These observations have significance for immuno-
therapeutic suppression of conditions in which ongoing tion utilized by certain infectious organisms. Signaling
through the DAP12-associated TREM-2 receptor wasantigen presentation is associated with chronic inflam-
mation, including autoimmune disease, allograft rejec- recently shown to activate human myeloid DCs in an
NFB-independent manner (Bouchon et al., 2001b). Al-tion and graft-versus-host disease. Of importance, in
the current studies induced Treg were capable of traffic though the ligands for TREM-2 are not yet known, infec-
tious organisms are likely candidates, based on the abil-from draining LN to spleen following s.c. administration
of DCs. After adoptive transfer, the Treg are likely to ity of bacteria to trigger the related TREM-1 receptor,
expressed by monocytes and neutrophils (Bouchon etsuppress DTH responses locally in the skin, but also to
suppress T cell proliferation in LN draining the site of al., 2001a). In addition, the relevance of CD40-CD154
interactions to T cell outcome appears to be stronglyantigen priming in the recipient animals. Further studies
on the capacity of the DC-induced regulatory T cells influenced by the APC, in that CD40-deficient BM-
derived myeloid DC and B cells are tolerogenic, whereasto traffic into, and to maintain suppressive function in
peripheral uninflamed or inflamed organs will be of im- other splenic APC—likely a splenic DC subset—are able
to stimulate allogeneic and Th2-type CD4 T cell re-portance in the context of autoimmune immunotherapy.
The NFB family of proteins is regulated by IB and sponses in vitro (Kumanogoh et al., 2001; Ozaki et al.,
1999). In this regard, DCs purified from chronically in-other inhibitory molecules in the cytosol. Cellular activa-
tion leads to IB phosphorylation and translocation of flamed, RelB-deficient spleen, that are enriched for the
CD8 subset, were reported to express higher levels ofactive NFB to the nucleus. RelB is translocated upon
myeloid DC differentiation, and it heterodimerizes with CD40 than DCs purified from wild-type spleen (Wu et al.,
1998). Therefore, RelB-independent pathways of CD40p50 in the DC nucleus (Neumann et al., 2000; O’Sullivan
and Thomas, 2002; Pettit et al., 1997). RelB- and p50- activation in response to inflammatory signals may par-
ticularly apply to certain splenic DC populations.deficient mice exhibit multiple deficits in immune func-
tion—in particular, RelB-deficient mice lack mature my- There are two broad explanations for the profound
suppression of immunity associated with deficiency ofeloid DCs and the liver and spleen are infiltrated by
myeloid cells, including monocytes, granulocytes, and CD40 expression by DC. First, generation of Treg might
be a default pathway resulting from inability of CD40-progenitor cells (Burkly et al., 1995; Sha et al., 1995).
The role of NFB in DC APC function was previously deficient DCs to upregulate key costimulatory mole-
cules, cytokines, or chemokines in response to CD40Lexamined in vivo through the use of NFB decoy oligo-
nucleotides (Giannoukakis et al., 2000). However, in (Cella et al., 1996). Alternatively, T cells signaled by
CD40-deficient DC might provide feedback non-CD40-these studies NFB inhibition was commenced several
days after the initiation of the DC cultures, and CD40 mediated signaling of the DC, thereby inducing other
APC-derived suppressive membrane or secreted mole-expression by BMDCs was not affected by the NFB
decoy. BAY 11-7082 has been shown previously to block cules. The latter model is conceptually appealing for
understanding the mechanism of suppression of a pre-NFB nuclear translocation through inhibition of IB
phosphorylation (O’Sullivan and Thomas, 2002; Pierce viously primed immune response. Whichever explana-
tion is correct, presentation of peptide to CD4 T cellset al., 1997). While nuclear translocation of all NFB
subunits was inhibited in BMDCs, the specificity of the in the absence of CD40 might represent a general mech-
anism of tolerance employed by several APC, includingdrug for NFB is unknown. However, we provide two
additional pieces of evidence that the consequences of myeloid DC and B cells (Buhlmann et al., 1995; Hollander
et al., 1996). Signaling of RelB through CD40 ligationantigen presentation by myeloid DCs are indeed deter-
mined by RelB activity. Thus, RelB-deficient BMDCs and induction of CD40 expression through RelB activity
represent an important feedback loop for the control ofconferred similar suppression to BMDCs generated
from wild-type mice in the presence of the inhibitor. antigen presentation (O’Sullivan et al., 2000; O’Sullivan
and Thomas, 2002). Similarly, inhibition either of CD40/Furthermore, the extent of nuclear RelB DNA binding
in DCs was inversely correlated with the induction of CD154 signaling or of RelB/p50 activity in APC may have
potent tolerogenic effects. For example, blockade ofsuppression by those cells.
The lack of CD40 expressed by RelB-deficient DCs CD40/CD154 interactions in vivo or use of CD154-defi-
cient recipients can prolong the life of allografts andand regulation of CD40 expression by RelB transfection
strongly suggested that CD40 could be a key determi- reduce severity of autoimmune diseases (Gao et al.,
1999; Hanninen et al., 2002). Furthermore, the capacitynant of the decision between tolerance and immunity
made by a T cell in response to DCs in lymphoid organs of various drugs and cytokines to inhibit NFB provides
a common mechanism linking their ability to retard the(Diehl et al., 2000; O’Sullivan et al., 2000). On the other
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ml penicillin, 100 g/ml streptomycin, 10 mM sodium pyruvate, 20differentiation of DCs (de Jong et al., 1999; Gregori et
mM HEPES, 2 mM L-glutamine, and 50 M 2-mercaptoethanol (cul-al., 2001; Mehling et al., 2000). In some cases, the re-
ture medium, CM). In all experiments where mBSA is used as thesulting DCs also prolong allograft acceptance in vivo
challenge antigen, DCs were cultured in serum-free Excell 620 cul-
(Gregori et al., 2001; Griffin et al., 2001). ture medium (CSL Biosciences), supplemented as above.
These data imply that the capacity of DCs prepared ex
vivo to suppress or prevent immunity can be predicted Bone Marrow-Derived Dendritic Cells (BMDCs)
based on the frequency of nuclear RelB DCs within Bone marrow cells were collected and suspended from murine long
bones and passed through nylon mesh, and mononuclear cells werethat population. By contrast, conditioning treatments
separated by ficoll gradient centrifugation. Macrophages, class IIthat maximize and sustain RelB translocation, such as
cells, and lymphocytes were immunodepleted using appropriateCD40 ligation and exposure to certain bacteria and vi-
mAb followed by magnetic beads (MACS, Miltenyi Biotec, CA). BM
ruses, would be predicted to stimulate Th1 and CTL cells were incubated for 6–8 days in CM supplemented with 10 ng/
responses most effectively (Hofer et al., 2001; O’Sullivan ml each GM-CSF and IL-4 (Peprotech, USA), with fresh medium
and Thomas, 2002; Ridge et al., 1998). The important applied alternate days. DC preparations routinely contained 80%–
90% CDllc cells. Some BMDCs were cultured continuously in therole played by RelB in immune responses is exemplified
presence of 5 M BAY 11-7082 (BioMol, Plymouth Meeting, PA) andby susceptibility of RelB-deficient mice to bacterial and
washed three times before use. For immature BMDCs, identicallyparasitic infection, lack of Th1 responses to viral infec-
treated BM cells were incubated for 8 days in CM, supplementedtion, and reduced susceptibility of RelB-deficient BM
with 0.5 ng/ml GM-CSF.
chimeras to inflammatory arthritis (Caamano et al., 1999;
Lawlor et al., 2001; Weih et al., 1997). The relatively weak Flow Cytometry
ability of immature DCs to suppress previously primed BMDCs were incubated for 30 min on ice with anti-CD86-FITC (GL1),
anti-CD11c-PE (HL3), anti-CD11b-PE (M1/70), CD8-PE (53-6.7),immune responses likely relates to a variable proportion
CD3-PE (17A2, all from PharMingen San Diego, CA), F4/80-PE (Sero-of nuclear RelB DCs within the preparations, de-
tec, Raleigh, NC), or with anti-CD40 (3/23), anti-MHC class II (2G9,pending on the methodology used. Furthermore, popu-
both from PharMingen), anti-CD19 (1D3, American Type Culturelations of immature DCs may be less likely to remain
Collection, ATCC), anti-Ly6-g and c (Gr1, RB6-BC5), or anti-CD45R
in an immature state after administration to previously (B220, RA3-6B2, each a gift from G. Hill, Queensland Institute for
primed animals, particularly at inflammatory sites, as Medical Research, Brisbane, Qld), and followed by biotinylated rab-
might occur in autoimmune disease (Pettit et al., 2000). bit anti-rat Ig (DAKO, CA) and then streptavidin-FITC (DAKO). Cells
were analyzed using a FACScalibur (BD-PharMingen). IntracellularThe current data highlight the potential for development
cytokine production was measured in lymphocytes by flow cytomet-of antigen-specific autoimmune immunotherapy using
ric staining as described, with minor modifications (Sander et al.,DCs treated with soluble inhibitors of NFB, in view of
1991). In brief, lymphocytes were stimulated in the presence ofthe potent suppression of CD40 expression without the
antigen or PMA/Ionomycin and brefeldin A for 18 hr, then stained
need for genetic manipulation of DC and the profound with FITC-CD4, followed by 4% paraformaldehyde fixation and per-
effect on previously primed immune responses in vivo. meabilization with saponin (Sigma, MO). Permeabilized cells were
As well as the immunotherapeutic possibilities, the stained with allophycocyanin (APC)-labeled anti-IL-10, APC-anti-
IL-4, or APC-anti-IFN- (all mAb from Pharmingen) for 30 min on ice.current studies also suggest a mechanism by which
peripheral tolerance might be constitutively maintained
Protein Extraction and Immunoblottingby myeloid DCs in which RelB and CD40 are either sup-
Nuclear and cytoplasmic extracts were prepared as previously de-pressed or not induced. We have previously demon-
scribed (Pettit et al., 1997) and protein estimated using a Proteinstrated that, in contrast to inflamed or lymphoid tissues,
Assay kit (Bio-Rad, Hercules, CA). 10 g of protein extract was
nuclear RelB cells are absent in noninflamed, non- separated by 8% SDS-PAGE. Following transfer to nitrocellulose
lymphoid peripheral tissues (Pettit et al., 2000, 1997; (Amersham, Sussex, England), membranes were immunoblotted
Thompson et al., 2002). Therefore, at sites of antigen with either anti-RelB (sc-226), anti-p50 (sc-7178), anti-c-Rel (sc-71),
anti-RelA (sc-109), or anti-p52 (sc-298) antibodies (all from Santauptake, myeloid immature DCs lack RelB. Furthermore,
Cruz Biotechnology), followed by sheep anti-rabbit HRP-conjugateda proportion of unmanipulated DCs in both periphery
Ig (Silenus, Hawthorn, Australia) and then detected by enhancedand LN has been shown to express little if any CD40
chemiluminescence (ECL, Life Technologies, MO).constitutively and to rely upon infectious signals for
CD40 induction and IL-12 production (Schulz et al.,
NFB Binding ELISA
2000). Since DCs containing apoptotic bodies can con- p50 and RelB DNA binding was detected by ELISA using a Mercury
stitutively migrate from peripheral sites to draining LN, Transfactor p50 Kit (Clontech, CA). 10 g of nuclear extract was
myeloid DCs may reach LN lacking RelB activity and cell bound to wells coated with NFB consensus oligonucleotide, in-
cubated with either anti-RelB or anti-p50 followed by anti-rabbitsurface CD40 (Huang et al., 2000). Crosspresentation of
HRP-conjugated Ig (Silenus), and then detected by measuring colorprocessed self-antigen derived from somatic cells could
development of TMB at 650 nm using a Multiskan plate readerthereby constitutively induce self-antigen-specific Treg
(Labsystems).in LN draining peripheral tissues. Thus, upstream signal-
ing of DCs by infectious antigen through TLR and other
Mice and Immunization
pattern recognition receptors that leads to RelB translo- C57BL/6 and BALB/c mice (Animal Resource Centre, Perth, Austra-
cation and CD40 induction provides a key pathway for lia) were maintained in specific pathogen-free (SPF) conditions. The
discrimination by the immune system of antigens loaded RelB mutant C57BL/6 mice were originally generated in D. Lo’s
laboratory (Burkly et al., 1995). They were bred under SPF conditionsby myeloid peripheral tissue DCs.
in the animal facility of the Walter and Eliza Hall Institute (WEHI).
Homozygous RelB/ mice were selected and supplied by Dr L. WuExperimental Procedures
(WEHI) at 5–7 weeks of age for BMDC generation. CD40-deficient
mice (Kawabe et al., 1994) were crossed for over ten generationsCulture Medium
under SPF conditions with BALB/c mice at the animal facility atDCs were cultured in RPMI plus 10% heat-inactivated fetal calf
serum (FCS, CSL, Parkville, Australia), supplemented with 100 g/ Australian National University (ANU), and homozygous CD40/
Immunity
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mice were supplied. IL-10 and MHC class II-deficient C57Bl/6 mice chemokine receptor 7 and maturation of human dendritic cells. J.
Exp. Med. 194, 1111–1122.were bred under SPF conditions and supplied from ANU. All s.c.
injections were delivered to the tailbase. Mice were immunized s.c. Buhlmann, J.E., Foy, T.M., Aruffo, A., Crassi, K.M., Ledbetter, J.A.,
with 60 g of mBSA or 50 g of keyhole limpet hemocyanin (KLH) Green, W.R., Xu, J.C., Shultz, L.D., Roopesian, D., Flavell, R.A., et
or 50 g of ovalbumin in complete Freunds adjuvant (CFA). Serum al. (1995). In the absence of a CD40 signal, B cells are tolerogenic.
antigen-specific Ab, draining lymph node (DLN) T cell proliferative Immunity 2, 645–653.
responses, and DTH responses were measured. For the DTH re-
Burkly, L., Hession, C., Ogata, L., Reilly, C., Marconi, L.A., Olson,sponses, mice were injected i.d with either 5 g of antigen or saline
D., Tizard, R., Cate, R., and Lo, D. (1995). Expression of relB isinto the ears and ear swelling was measured and scored 24 hr later
required for the development of thymic medulla and dendritic cells.using an engineer’s micrometer. For the adoptive transfer experi-
Nature 373, 531–536.ments, C57BL/6 mice were injected s.c. with 5  105 KLH-pulsed
BMDCs. Spleens were removed 7 days later, and splenocytes were Caamano, J., Alexander, J., Craig, L., Bravo, R., and Hunter, C.A.
(1999). The NF-kappa B family member RelB is required for innateenriched for T cells by transfer to sterile nylon wool columns (Rob-
bins Scientific, Sunnyvale, CA) for 1 hr at 37C. In some experiments, and adaptive immunity to Toxoplasma gondii. J. Immunol. 163,
4453–4461.CD3CD4 and CD3CD4 cells were sorted, after staining with
anti-CD3-FITC and anti-CD4-PE, using a Moflo flow cytometer (Cy- Cella, M., Scheidegger, D., Palmer Lehmann, K., Lane, P., Lanzavec-
tomation, Fort Collins, CO). Purity was approximately 85%. In other chia, A., and Alber, G. (1996). Ligation of CD40 on dendritic cells
experiments, CD3CD4 T cells were purified by immunomagnetic triggers production of high levels of interleukin-12 and enhances T
depletion with anti-CD8, anti-MHC class II, Gr1, B220, and F4/80. cell stimulatory capacity: T-T help via APC activation. J. Exp. Med.
2.5–5 105 of each purified population was injected i.v. into nonirra- 184, 747–752.
diated syngeneic recipients, primed 7–9 days previously with either
Cobbold, S., and Waldmann, H. (1998). Infectious tolerance. Curr.KLH or ovalbumin in CFA. Antigen-specific T cell proliferative re-
Opin. Immunol. 10, 518–524.sponses were measured in DLN after 7 days. For in vivo mAb
blocking studies, recipient mice were administered 1 mg anti-IL- de Jong, E.C., Vieira, P.L., Kalinski, P., and Kapsenberg, M.L. (1999).
Corticosteroids inhibit the production of inflammatory mediators in10R mAb (1B1.3a, PharMingen) or isotype control mAb i.p. 4 hr
before transfer of CD3CD4 T cells. immature monocyte-derived DC and induce the development of
tolerogenic DC3. J. Leukoc. Biol. 66, 201–204.
In Vitro Proliferative and Antibody Responses Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C., and
For the T cell proliferation assay, a single-cell suspension was pre- Bhardwaj, N. (2001). Antigen-specific inhibition of effector T cell
pared from the inguinal LNs. 4  105 LN cells/well were incubated function in humans after injection of immature dendritic cells. J.
in triplicate in the presence or absence of varying concentrations Exp. Med. 193, 233–238.
of antigen or 1 g Concanavalin A (Sigma), at 37C in 5% CO2 for
Diehl, L., Den Boer, A.T., van der Voort, E.I., Melief, C.J., Offringa,3 days. In all experiments where mBSA is used as the challenge
R., and Toes, R.E. (2000). The role of CD40 in peripheral T cellantigen, assays were carried out in serum-free Excell 620 culture
tolerance and immunity. J. Mol. Med. 78, 363–371.medium. Cells were pulsed with 1 Ci 3 H-thymidine/well for the final
Feldmann, M. (2001). Pathogenesis of arthritis: recent research6–8 hr, then harvested onto glass fiber filters using an automated cell
progress. Nat. Immunol. 2, 771–773.harvester. Incorporated 3 H-thymidine was counted using a Packard
TopCount NXT (Packard, Meriden, CT). Specific [3 H]-thymidine in- Gao, J.X., Madrenas, J., Zeng, W., Cameron, M.J., Zhang, Z., Wang,
corporation (cpm) was the mean  SEM of triplicate wells. J.J., Zhong, R., and Grant, D. (1999). CD40-deficient dendritic cells
For mBSA or KLH-specific Ab determination by ELISA, serum was producing interleukin-10, but not interleukin-12, induce T-cell hypo-
prepared from lateral tail vein blood. 100 l of mBSA or KLH protein, responsiveness in vitro and prevent acute allograft rejection. Immu-
at 10 g/ml in 50 mM carbonate buffer (pH 9.6), was coated onto the nology 98, 159–170.
wells of 96-well microtiter plates (Griener Labortechnik, Kresmuster,
Giannoukakis, N., Bonham, C.A., Qian, S., Zhou, Z., Peng, L., Har-Austria). After washing with 0.5% Tween 20/PBS and blocking with
naha, J., Li, W., Thomson, A.W., Fung, J.J., Robbins, P.D., and Lu,200 l 3% BSA fraction V, 100 l serum in 5-fold dilutions was
L. (2000). Prolongation of cardiac allograft survival using dendriticadded to duplicate wells. After washing, each well was incubated
cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol.with 100 l of biotinylated rabbit anti-mouse Ig secondary antibody
Ther. 1, 430–437.(DAKO), followed by washing and incubation with streptavidin-
Gregori, S., Casorati, M., Amuchastegui, S., Smiroldo, S., Davalli,horseradish peroxidase. After incubation with 0.1% ABTS in 0.03%
A.M., and Adorini, L. (2001). Regulatory T cells induced by 1alpha,25-hydrogen peroxide and 150 mM citrate buffer (pH 4.5), the presence
dihydroxyvitamin d(3) and mycophenolate mofetil treatment mediateof antigen-specific antibodies was detected by the net absorbance
transplantation tolerance. J. Immunol. 167, 1945–1953.readings at 405 nm and 492 nm.
Griffin, M.D., Lutz, W., Phan, V.A., Bachman, L.A., McKean, D.J.,
Statistical Analysis and Kumar, R. (2001). Dendritic cell modulation by 1alpha,25 dihy-
Differences were compared using Student’s t tests. Differences droxyvitamin D3 and its analogs: a vitamin D receptor-dependent
were considered significant at p 	 0.05. pathway that promotes a persistent state of immaturity in vitro and
in vivo. Proc. Natl. Acad. Sci. USA 98, 6800–6805.
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